OTCMKTS:BETRF BetterLife Pharma (BETRF) Stock Price, News & Analysis $0.07 +0.00 (+2.94%) As of 04/25/2025 09:30 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About BetterLife Pharma Stock (OTCMKTS:BETRF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BetterLife Pharma alerts:Sign Up Key Stats Today's Range$0.07▼$0.0750-Day Range$0.05▼$0.0952-Week Range$0.05▼$0.15Volume1,200 shsAverage Volume14,928 shsMarket Capitalization$9.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.Read More… BetterLife Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreBETRF MarketRank™: BetterLife Pharma scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for BetterLife Pharma. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of BetterLife Pharma is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BetterLife Pharma is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BetterLife Pharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the float of BetterLife Pharma has been sold short.Short Interest Ratio / Days to CoverBetterLife Pharma has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BetterLife Pharma has recently decreased by 33.79%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBetterLife Pharma does not currently pay a dividend.Dividend GrowthBetterLife Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.01% of the float of BetterLife Pharma has been sold short.Short Interest Ratio / Days to CoverBetterLife Pharma has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BetterLife Pharma has recently decreased by 33.79%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for BetterLife Pharma this week, compared to 0 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BetterLife Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders34.77% of the stock of BetterLife Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.01% of the stock of BetterLife Pharma is held by institutions.Read more about BetterLife Pharma's insider trading history. Receive BETRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BetterLife Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address BETRF Stock News HeadlinesBetterLife Pharma With CEO, Ahmad DoroudianApril 25 at 2:36 PM | msn.comBetterLife appoints Andre Beaudry as corporate advisorApril 4, 2025 | markets.businessinsider.comTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying on cheap foreign hardware—just saw their costs shoot through the roof. For the other group of AI companies, they were just handed a massive competitive advantage. Make no mistake, AI as a whole is still a game-changer for the global economy. But within the AI sector, Trump’s tariffs have created a huge divergence.April 26, 2025 | Traders Agency (Ad)BetterLife Pharma Appoints Corporate AdvisorApril 3, 2025 | financialpost.comBetterLife Pharma Appoints Corporate AdvisorApril 3, 2025 | globenewswire.comBetterLife Pharma Appoints New DirectorMarch 31, 2025 | financialpost.comBetterLife Pharma Appoints New DirectorMarch 31, 2025 | globenewswire.comBetterLife Pharma Inc.: BetterLife Announces Debt ConversionsMarch 10, 2025 | finanznachrichten.deSee More Headlines BETRF Stock Analysis - Frequently Asked Questions How have BETRF shares performed this year? BetterLife Pharma's stock was trading at $0.0720 at the beginning of 2025. Since then, BETRF shares have decreased by 2.8% and is now trading at $0.07. View the best growth stocks for 2025 here. How do I buy shares of BetterLife Pharma? Shares of BETRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today4/26/2025Next Earnings (Estimated)5/27/2025Fiscal Year End1/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:BETRF CIK1464165 Webwww.abetterlifepharma.com Phone604-221-0595FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,140,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-999.57% Debt Debt-to-Equity RatioN/A Current Ratio0.05 Quick Ratio0.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-1.40Miscellaneous Outstanding Shares129,463,000Free Float84,449,000Market Cap$9.06 million OptionableNot Optionable Beta1.47 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (OTCMKTS:BETRF) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BetterLife Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BetterLife Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.